Document is current
Any future updates will be listed below
-
Authors
Chiriaco, Cristina
Donini, Chiara
Cortese, Marco
Ughetto, Stefano
Modica, Chiara
Martinelli, Ilaria
Proment, Alessia
Vitali, Letizia
Fontani, Lara
Casucci, Monica
Comoglio, Paolo Maria
Giordano, Silvia
Sangiolo, Dario
Leuci, Valeria
Vigna, Elisa http://orcid.org/0000-0001-9787-5732
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (5 per Mille 2018 - ID 21052, IG 2017 - ID 20259, IG 2017 – ID 20210, IG 2019 - ID 23820)
Ministero della Salute (ricerca corrente 2018-2021, RCR-2019-23669115)
- License Information
-
More Information
Article History
Received: 9 May 2022
Accepted: 30 August 2022
First Online: 21 October 2022
Declarations
:
: All procedures in mice adhered to the “Animal Research: Reporting of In Vivo Experiments” (ARRIVE) standards and were approved by the Ethical Commission of the Candiolo Cancer Institute (Candiolo, Torino, Italy), and by the Italian Ministry of Health. All patients provided written informed consent; samples were collected and the study was conducted under the approval of the review boards of the Candiolo Cancer Institute. The study was done in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization, and Good Clinical Practice guidelines and GDPR (General Data Protection Regulation).
: All authors who contributed to the study agree to publish it.
: PMC and EV are co-founders of Metis Precision Medicine B-Corp (Torino, Italy). PMC and EV are authors of the patent application N. PCT/EP2019/077116 “Novel therapeutic agent for the treatment of a tumor and/or metastasis”. The other authors declare no potential conflict of interest.
